Altimmune (ALT)

• Market cap: $527M
• 1 day: -7.19%
• 5 days: -10.26%
• 1 month: -11.44%
• 3 months: -22.79%
• 6 months: -48.28%
• Year to date: -22.79%
• 1 year: -50.37%
• 5 years: -79.78%
• 10 years: -99.6%
• Sector: Healthcare
• Industry: Biotechnology

About: Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 57